Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Patent metadata

Field	Value
Publication number	US-12428425-B2
Application number	US-202318472147-A
Country	US
Kind code	B2
Filing date	Sep 21, 2023
Priority date	May 4, 2020
Publication date	Sep 30, 2025
Grant date	Sep 30, 2025

Abstract

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).

This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

First claim

What is claimed is:

1. A method of treating Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, Nasu-Hakola disease, multiple sclerosis, or stroke in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound selected from:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

2. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

3. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

4. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

5. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

6. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

7. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

8. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

9. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

10. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

11. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

12. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

13. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

14. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

15. The method of claim 1 , wherein the compound is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

16. The method of claim 1 , wherein the disease or condition is Alzheimer's disease.

17. The method of claim 1 , wherein the disease or condition is Nasu-Hakola disease.

18. The method of claim 1 , wherein the compound or tautomer thereof, or pharmaceutically acceptable salt of said compound or said tautomer is administered as a pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound or tautomer thereof, or pharmaceutically acceptable salt of said compound or said tautomer.

Assignees

• Amgen Inc
• Vigil Neuroscience Inc

Inventors

• Czabaniuk Lara C
• Hopper Timothy
• Houze Jonathan B
• Panteleev Jane
• Rescourio Gwenaella
• Santora Vincent
• Wang Haoxuan
• White Ryan D
• Wong Alice R
• Wu Yongwei
• Bos Maxence
• Mancuso John
• Franzoni Ivan

Classifications

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C07D475/00 Primary

  Heterocyclic compounds containing pteridine ring systems · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title